Spot on mate. Based on Recce's current pace in trials and clear shift to gain an income stream from eastern countries in order to minimise dilution, I can't see us seeing a RCE drug in westen markets this decade. Any work in this space is more or less for long term, or just to keep the employees (family) busy to justify their exorbitant wages.
Ann: Approval to Start Phase I/II Diabetic Foot Ulcer Study, page-16
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.0¢ |
Change
0.010(2.17%) |
Mkt cap ! $104.2M | |||
| Open | High | Low | Value | Volume |
| 46.5¢ | 47.0¢ | 46.0¢ | $34.35K | 73.86K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 222366 | 46.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 47.0¢ | 42188 | 4 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| RCE (ASX) Chart |